What is the correct order of medications for suspected hyperkalemia?

What is the correct order of medications for suspected hyperkalemia?

• A. ALBUTEROL 2.5 mg in 3 mL continuous SVN OR LEVALBUTEROL 1.25 mg in 3 mL continuous SVN; CALCIUM CHLORIDE 1 g slow IVP/IO; SODIUM BICARBONATE 50 mEq slow IVP/IO
• B. CALCIUM CHLORIDE 1 g slow IVP/IO; SODIUM BICARBONATE 50 mEq slow IVP/IO; ALBUTEROL 2.5 mg in 3 mL continuous SVN
• C. SODIUM BICARBONATE 50 mEq slow IVP/IO; ALBUTEROL 2.5 mg in 3 mL continuous SVN; CALCIUM CHLORIDE 1 g slow IVP/IO
• D. ALBUTEROL 2.5 mg in 3 mL continuous SVN; SODIUM BICARBONATE 50 mEq slow IVP/IO; CALCIUM CHLORIDE 1 g slow IVP/IO

Answer: (A)

When managing suspected hyperkalemia, the goal is to protect the heart, rapidly lower extracellular potassium, and correct contributing factors like acidosis. The fastest step to reduce potassium’s effect is to drive potassium into cells, which is achieved with a nebulized beta-agonist like albuterol. This acts quickly through beta-2 receptors to stimulate the Na+/K+-ATPase pump, lowering serum potassium within minutes. Calcium chloride is then given to stabilize cardiac membranes. It doesn’t lower potassium, but it raises the threshold for excitability and helps prevent malignant arrhythmias as potassium shifts occur. Providing this membrane stabilization after the initial shift onset reduces the risk of conduction disturbances during therapy. Finally, sodium bicarbonate is administered to address acidosis and further promote intracellular shifting of potassium. Its effect helps augment the overall potassium reduction, especially when metabolic acidosis is present. So the sequence—start with rapid potassium shift via albuterol, follow with calcium for cardiac protection, and finish with bicarbonate to support ongoing potassium reduction and correct acidosis—optimizes safety and effectiveness in an emergency hyperkalemia scenario.

When managing suspected hyperkalemia, the goal is to protect the heart, rapidly lower extracellular potassium, and correct contributing factors like acidosis. The fastest step to reduce potassium’s effect is to drive potassium into cells, which is achieved with a nebulized beta-agonist like albuterol. This acts quickly through beta-2 receptors to stimulate the Na+/K+-ATPase pump, lowering serum potassium within minutes.

Calcium chloride is then given to stabilize cardiac membranes. It doesn’t lower potassium, but it raises the threshold for excitability and helps prevent malignant arrhythmias as potassium shifts occur. Providing this membrane stabilization after the initial shift onset reduces the risk of conduction disturbances during therapy.

Finally, sodium bicarbonate is administered to address acidosis and further promote intracellular shifting of potassium. Its effect helps augment the overall potassium reduction, especially when metabolic acidosis is present.

So the sequence—start with rapid potassium shift via albuterol, follow with calcium for cardiac protection, and finish with bicarbonate to support ongoing potassium reduction and correct acidosis—optimizes safety and effectiveness in an emergency hyperkalemia scenario.